VBIV News and Press, VBI Vaccines Inc. From 07/12/22

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer. Mr. Dillman will be respons...

VBI Vaccines (NASDAQ:VBIV) said that its 3-antigen hepatitis B (HBV) vaccine was more effective than GlaxoSmithKline's (GSK) Engerix-B, a single-antigen vaccine, based on phase 3, long-term follow-up data. VBI (VBIV) found that based on a follow-up analysis, participants who received the 3-an...

- Presentation title: “Long-Term Persistence of Anti-HBs Antibodies after Vaccination with a 3-Antigen HBV Vaccine Compared with a Single-Antigen HBV Vaccine” VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pu...

VBI Vaccines (NASDAQ:VBIV) on Wednesday said that the U.S. FDA had granted an orphan drug designation to its vaccine candidate VBI-1901 for the treatment of glioblastoma (GBM), an aggressive type of brain cancer. The FDA's orphan drug designation program expedites the development an...

- FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients - Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated...

Check These 3 Biotech Penny Stocks Out For Your Watchlist If you’re looking for biotech penny stocks to buy, there are hundreds of options to choose from. And while it may seem simple, it can be quite an arduous process to find biotech stocks that are worth investing in. Whil...

VBI Vaccines (NASDAQ:VBIV) and Hepion Pharmaceuticals (HEPA) are trading sharply higher on Friday after the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designations for two of thier cancer candidates. According to a federal register, the FDA has granted the designation for a b...

VBI Vaccines recently reported updated data from their VBI-1901 candidate in recurrent Glioblastoma. The company publicized the median overall survival and 18-month overall survival data are outperforming historical controls. VBI-1901 is showing its ability to have an impact on the tu...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the Jefferie...

Updated phase 2 data from VBI Vaccines' (NASDAQ:VBIV) cancer vaccine candidate VBI-1901 found 18-month overall survival of 25% in one arm and 40% in another in recurrent glioblastoma (GBM). In the first arm, VBI-1901 was adjuvanted with granulocyte macrophage colony-stimulating factor (GM-CSF...